Antibody Ingredients TRIZ Cases

NJ001-1 resolves limited early detection and unsatisfactory therapeutic effects by inducing apoptosis in lung adenocarcinoma and squamous carcinoma tissues.

An anti-LR11 antibody detects LR11 protein on malignant tumor cell surfaces, resolving inconsistent soluble marker levels in blood samples.

Human framework monoclonal antibodies target TSPAN33 on activated B cells, sparing resting B cells and reducing infection risks from broad-spectrum therapies.

Humanized anti-TfR antibodies preserve murine CDRs to maintain binding affinity while reducing immunogenicity through localized constant region modification.

Pairing CD123-targeted antibodies with saponin-based adjuvants overcomes quiescent leukemic stem cell resistance to improve treatment reliability.

Radiolabeled anti-CD8 antibodies visualize tissue expression to monitor tumor therapy response while minimizing off-target immunogenicity.

Monoclonal antibodies bind to the ROR1 receptor protein, inhibiting signaling pathways and reducing leukemic cell burden.

Bispecific antibody bridges PD-1 on T-cells with PD-L1 on tumor cells, overcoming immune suppression to inhibit tumor growth.

Anti-EGFR monoclonal antibodies reduce inflammation and mortality while preserving immunocompetence in hypoxemic acute respiratory failure.

Fc-free bispecific antibody formats eliminate toxic effector functions while maintaining T cell engagement capabilities.

Antibodies binding glucocorticoid-induced tumor necrosis factor receptor enhance anti-tumor immune responses through specific antigen interactions.

Stapled single-chain variable fragments incorporate disulfide bonds to reduce aggregation and improve stability of CD3 binding agents.

A rotary knife cuts poultry necks while a cylinder twists the head to expose veins, solving friction-induced twisting that compromises cutting reliability.

Bispecific antibody prevents CD16 shedding on NK cells, sustaining cytotoxic activity against FOLR1-expressing tumors.

Antibody variable regions target FCMR signaling to treat inflammatory and autoimmune diseases.

A drug-molecule conjugate binds to CAR receptors on T cells, inducing internalization and selective inhibition of cellular activity.

Anti-TREM2 antibodies eliminate immunosuppressive myeloid cells, resolving resistance in cancer treatment.

Coadministers acyl thiourea CSF1R inhibitors with PD-1 antagonists to deplete tumor-associated macrophages while boosting T cell immunity.

Anti-CD163 antibodies inhibit PRRSV infection by binding SRCR5 epitopes, avoiding complex genetic modification.

Anti-OX40L antibodies treat moderate-to-severe atopic dermatitis by extending dosing intervals to every 12 weeks while maintaining therapeutic control.

Targeting the C2 domain of EGFR with specific antibodies improves suppression efficacy against KRAS mutant malignant tumor cells.

Multi-specific binding proteins engage NKG2D and CD16 receptors on natural killer cells to activate targeted immune responses.

Antibody tumor-targeting assembly complexes activate CD8+ T cells via protease-cleavable linkers.

Segmenting checkpoint inhibition into a single bispecific agent reduces systemic toxicity while enhancing T-cell activation at the tumor site.

Engineered CDR sequences resolve low affinity bottlenecks in existing antibodies to effectively block PD-1 interactions with PD-L1 and PD-L2.

Antibodies bind human TIGIT protein to inhibit interaction with CD155 ligands, restoring T cell activation against cancer cells.

Chimeric small molecules recruit endogenous antibodies to prostate cancer cells, reducing side effects and cost versus monoclonal therapies.

Crystal structure determination resolves limited structural information on antibody binding mechanisms, enabling targeted polypeptide design.

Combining CSF-1R and CD20 antibodies overcomes macrophage protection to enhance treatment efficacy.

Sequential dosing of CD20 and BLyS antibodies prevents B-cell relapse and improves immunological tolerance in autoimmune disorders.

Multi-specific antibodies suppress HER3 signaling to overcome tumor resistance against existing EGFR and HER2 inhibitor therapies.

Masking the CD3 binding moiety with an anti-idiotype prevents premature activation, resolving on-target/off-tumor toxicity in cancer therapy.

Specific antibodies bind mouse and human NGLY1 to resolve non-specific detection in Congenital Disorders of Glycosylation Type IV diagnosis.

An anti-CSF-1R antibody blocks CSF-1R signaling to resolve poor prognosis in idiopathic pulmonary fibrosis.

A bispecific antibody engages CD16 and CD112R receptors to activate immune cells.

An ADAM17 inhibitory antibody suppresses vascular remodeling induced by angiotensin II.

An anti-domain IV EGFR antibody induces ADCC against cancer cells.

Detecting PCSK6 autoantibodies identifies membranous nephropathy cases requiring targeted immunosuppressive therapy.

Novel IgE antibodies form ternary complexes with host-derived non-tumor cells to reprogram the tumor microenvironment and inhibit metastasis.

T1h humanized monoclonal antibody targets CD6 molecules on tumor cells to induce apoptosis without causing prolonged lymphopenia.

Administers PD-1 inhibitors alongside long-acting IL-2Rβ agonists and TLR7/8 agonists to overcome immune suppression.

Multispecific antibodies bind TRGV9 and cancer antigens to recruit gamma delta T cells, resolving low potency in conventional redirection.

Antibodies bind CSF1R to inhibit macrophage activity, reducing inflammation and bone destruction in rheumatoid arthritis.

Multispecific antibodies redirect Vγ9Vδ2 T-cells to CD33+ cancer cells, overcoming heterogeneous AML blast targeting limitations.

Chimeric anti-HLA-G antibodies inhibit ILT2 binding to restore suppressed immune responses while avoiding cross-reactivity with other HLA family members.

Stratifying patients by lymphatic status rather than PD-1 expression improves survival for low-expression tumors.

Bispecific antibodies bind FLT3 and CD3 receptors to redirect T-cell cytotoxicity toward hematopoietic stem cells.

Administering an ALK inhibitor alongside bevacizumab improves tumor response while resolving the trade-off between angiogenesis blockade and drug penetration.

Single-chain T cell engager molecules combine scFab and scFv domains to bind target antigens and CD3 receptors.

Combining anti-CCR7 antibodies with BTK or Bcl-2 inhibitors overcomes resistance in refractory B-cell malignancies.